GO:0043559 insulin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043559 insulin binding is a molecular function defined as binding to insulin, the polypeptide hormone produced by pancreatic islets.
• Insulin binding is mediated by the insulin receptor (INSR) and is characterized by negative cooperativity, where binding of one insulin molecule reduces the affinity for subsequent molecules.
• The receptor-binding region of insulin involves specific residues such as A3, and mutations like insulin Wakayama alter binding affinity.
• Insulin binding can be monitored by advanced techniques such as fluorescence correlation spectroscopy and is studied in cells like human erythrocytes.
• Defects in insulin binding are linked to diabetes and autoimmune conditions, with proinsulin variants explored as targeting ligands.
• Understanding insulin binding informs therapeutic design and requires precise CRISPR models to dissect gene function.
Description
Insulin binding (GO:0043559) is a fundamental molecular function that initiates the metabolic and mitogenic actions of insulin. This process is critical for glucose homeostasis and is dysregulated in diabetes and related disorders. The binding event occurs primarily at the insulin receptor (INSR), a receptor tyrosine kinase, and involves specific structural determinants on both insulin and the receptor. Researchers study insulin binding to understand hormone signaling, receptor activation, and to develop therapeutic interventions. The affinity and kinetics of this interaction are modulated by factors such as negative cooperativity and mutations in insulin or its receptor. Experimental models range from human erythrocytes to engineered cell lines, enabling detailed mechanistic and pharmacological investigations.
insulin binding At A Glance
| GO ID | GO:0043559 |
|---|---|
| GO term | insulin binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to insulin hormone, initiating receptor-mediated signaling |
| Definition source | QuickGO |
| Related diseases | Diabetes mellitus, insulin resistance, autoimmune diabetes |
| Key molecules | INSR, insulin (INS), IGF1R, proinsulin variants |
What Is GO:0043559?
GO:0043559 insulin binding is defined as the molecular function of binding to insulin, a polypeptide hormone produced by the islets of Langerhans in the pancreas of mammals and by homologous organs in other organisms. This binding event is the initial step in insulin signaling and is mediated by specific receptors and binding proteins.
Why Is insulin binding Important in Cell Biology?
Insulin binding is essential for normal glucose metabolism and its dysregulation is a hallmark of diabetes and metabolic syndrome. Understanding the molecular details of insulin binding provides insights into receptor activation, negative cooperativity, and the structural basis of hormone action, which are critical for designing insulin analogs and receptor-targeted therapies.
• Initiates insulin signaling cascades that regulate glucose uptake and metabolism.
• Negative cooperativity modulates receptor occupancy and signaling duration.
• Mutations in insulin or its receptor alter binding affinity and cause diabetes.
• Insulin binding is a target for therapeutic insulin analogs and delivery systems.
• Autoimmune diabetes involves insulin-binding B cells, making it relevant to disease pathogenesis.
• Fluorescence correlation spectroscopy enables real-time monitoring of insulin binding.
• Human erythrocytes provide a model to study insulin binding and degradation.
• Binding site 2 mutations affect receptor specificity and downstream responses.
• Structural studies of insulin-receptor interactions inform drug design.
• Insulin binding assays are used in clinical and research settings to assess receptor function.
What Happens During insulin binding?
Insulin Recognition and Initial Contact
In simple terms: Insulin first attaches to the outside of the receptor.
The binding process begins when insulin, a small polypeptide hormone, recognizes and docks onto the extracellular domain of the insulin receptor (INSR). This interaction involves specific residues on insulin, such as the A3 valine, and complementary sites on the receptor. The initial contact is reversible and governed by affinity constants that can be measured using techniques like fluorescence correlation spectroscopy.
Negative Cooperativity and Receptor Occupancy
In simple terms: Once one insulin binds, it becomes harder for others to bind.
Insulin binding exhibits negative cooperativity, meaning that the binding of one insulin molecule reduces the affinity of the receptor for additional insulin molecules. This phenomenon is a key regulatory mechanism that shapes the dose-response curve and signaling outcomes. Structural studies have elucidated the basis for this cooperativity, which involves conformational changes in the receptor dimer.
Receptor Activation and Signaling Initiation
In simple terms: Binding triggers a signal inside the cell.
Upon insulin binding, the insulin receptor undergoes autophosphorylation and activates its intrinsic tyrosine kinase activity. This leads to phosphorylation of downstream substrates such as IRS proteins, initiating metabolic and mitogenic signaling pathways. The binding event is therefore the critical switch that converts an extracellular hormonal signal into intracellular responses.
Binding Site 2 and Hormone Specificity
In simple terms: A second site on the hormone helps determine which receptor it activates.
Insulin and insulin-like growth factors (IGFs) share structural homology but differ in receptor specificity. Mutations at the hypothetical binding site 2 of insulin and IGFs result in receptor- and hormone-specific responses, indicating that this region contributes to binding selectivity and downstream signaling. This specificity is important for distinguishing metabolic versus growth-promoting effects.
Key Genes Involved in GO:0043559 insulin binding
The following genes and proteins are central to insulin binding and its regulation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| INS | Encodes insulin hormone | Mutations alter binding affinity and cause diabetes |
| INSR | Insulin receptor; mediates binding and signaling | Primary receptor for insulin binding; target of mutational studies |
| IGF1R | Insulin-like growth factor 1 receptor | Cross-reacts with insulin at high concentrations; binding specificity studies |
| IRS1 | Insulin receptor substrate 1 | Downstream signaling; not directly binding but affected by binding |
| IRS2 | Insulin receptor substrate 2 | Downstream signaling; metabolic effects |
| PTPN1 | Protein tyrosine phosphatase 1B | Regulates receptor phosphorylation; not a binding protein |
| ENPP1 | Ectonucleotide pyrophosphatase/phosphodiesterase 1 | Inhibits insulin receptor; not a direct binder |
| SLC2A4 | GLUT4 glucose transporter | Downstream of insulin binding; translocation |
| AKT1 | Serine/threonine kinase | Downstream signaling; not a binder |
| MAPK1 | Mitogen-activated protein kinase 1 | Downstream signaling; not a binder |
| INSR | Insulin receptor (isoforms) | Alternative splicing affects binding |
| INS | Insulin (preproprotein) | Processing affects binding |
| IGF2 | Insulin-like growth factor 2 | Competes for binding |
| INSL3 | Insulin-like 3 | Related hormone; binding not well characterized |
| INSL4 | Insulin-like 4 | Related hormone; binding not well characterized |
| INSL5 | Insulin-like 5 | Related hormone; binding not well characterized |
| INSL6 | Insulin-like 6 | Related hormone; binding not well characterized |
How Is insulin binding Regulated?
Insulin binding is regulated at multiple levels. Negative cooperativity modulates receptor occupancy and signaling intensity. The expression levels of insulin and its receptor are controlled transcriptionally and post-translationally. Additionally, binding site 2 mutations in insulin and IGFs can alter receptor-specific responses, indicating intrinsic regulatory mechanisms. Downstream feedback loops, such as those involving phosphatases, also influence the duration of binding-induced signaling.
insulin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| INS | Neonatal diabetes, insulin Wakayama | Knock-in mouse expressing mutant insulin |
| INSR | Insulin resistance, type A insulin resistance syndrome | Point-mutation knock-in cell lines |
| INS | Autoimmune diabetes | B-cell targeting assays with proinsulin variants |
| IGF1R | Growth disorders, cancer | Binding specificity studies with mutant ligands |
| INSR | Metabolic syndrome | Overexpression and knockout models |
Diabetes Mellitus and Insulin Resistance
Defects in insulin binding or receptor function are central to diabetes pathogenesis. Mutations in the insulin gene, such as insulin Wakayama, reduce receptor binding affinity and cause neonatal diabetes or MODY. Insulin resistance, a hallmark of type 2 diabetes, often involves impaired receptor binding or downstream signaling. Studying insulin binding helps elucidate these mechanisms and guides therapeutic development.
Autoimmune Diabetes
In autoimmune diabetes, insulin-binding B cells play a role in disease pathogenesis. Proinsulin variants, such as proinsulin(F25D), have been evaluated as targeting ligands for these B cells, offering potential for targeted therapies. This highlights the importance of insulin binding in immune-mediated beta-cell destruction.
Metabolic Syndrome and Related Disorders
Altered insulin binding can contribute to metabolic syndrome, obesity, and cardiovascular disease. Understanding the structural basis of binding and negative cooperativity provides insights into how these conditions develop and may reveal new drug targets.
From insulin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a specific insulin mutation alter receptor binding affinity? | Point-mutation knock-in of INS in cell lines |
| What is the role of INSR in insulin binding and signaling? | INSR knockout or knockdown cells |
| How does negative cooperativity affect signaling? | Receptor dimer mutants with tagged knock-in |
| Can proinsulin variants target insulin-binding B cells? | Overexpression of proinsulin(F25D) in B-cell lines |
| What is the binding specificity of IGFs versus insulin? | Site-2 mutants of IGF1 and IGF2 in knock-in models |
| How does insulin binding change in diabetes? | Patient-derived cells or CRISPR-edited iPSCs |
How to Study the insulin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescence correlation spectroscopy | Binding kinetics and affinity | Real-time monitoring of insulin binding |
| Radioligand binding assay | Receptor number and affinity | Characterization of insulin receptors on cells |
| Surface plasmon resonance | Binding kinetics (kon, koff) | Label-free interaction analysis |
| Isothermal titration calorimetry | Thermodynamics of binding | Energetics of insulin-receptor interaction |
| Molecular dynamics simulation | Binding free energy and conformational changes | Predicting effects of mutations |
| Western blot | Receptor phosphorylation and downstream signaling | Functional validation of binding |
| Glucose uptake assay | Metabolic response to insulin | Functional outcome of binding |
Fluorescence Correlation Spectroscopy (FCS)
FCS allows real-time monitoring of insulin binding to receptors in solution or on cell surfaces. It measures fluctuations in fluorescence to determine binding kinetics and affinity, as demonstrated for insulin binding. This method is highly sensitive and can be applied to live cells.
Radioligand Binding Assays
Classical radioligand binding assays using 125I-insulin are used to quantify binding affinity, receptor number, and competition. These assays have been applied to human erythrocytes to study insulin binding and degradation at physiological temperature. They remain a gold standard for receptor characterization.
Structural Biology and Computational Modeling
X-ray crystallography, cryo-EM, and molecular dynamics simulations provide atomic-level insights into insulin-receptor interactions. For example, λ-dynamics simulations have been used to investigate binding affinities of insulin Wakayama and other A3 variants. These methods complement experimental binding studies.
Cell-Based Signaling Assays
Downstream signaling events such as receptor autophosphorylation, Akt phosphorylation, and glucose uptake can be measured to assess functional consequences of insulin binding. These assays are often performed in cell lines overexpressing wild-type or mutant receptors.
How CRISPR Can Be Used to Study GO:0043559 insulin binding
Knockout
CRISPR knockout of INSR or INS can abolish insulin binding, providing a null background to study receptor function and signaling. Knockout cell lines are valuable for validating specificity of binding assays and for identifying compensatory mechanisms.
Point Mutation
Point mutations in INS or INSR can be introduced to mimic naturally occurring variants such as insulin Wakayama. These models allow precise dissection of binding affinity changes and downstream signaling defects, as studied in structural and computational analyses.
Knock-in
Knock-in of tagged or mutant receptors enables visualization and tracking of insulin binding in live cells. For example, fluorescently tagged INSR knock-in models can be used with advanced imaging to study receptor trafficking and cooperativity.
Overexpression
Overexpression of wild-type or mutant insulin receptors in cell lines increases binding capacity and signal strength, facilitating biochemical and pharmacological studies. This approach is commonly used to study insulin binding and negative cooperativity.
How EDITGENE Supports insulin binding Research
Researchers studying insulin binding-related genes often need to determine whether a candidate gene is causally involved in binding, signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to create precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for insulin binding research.
Frequently Asked Questions About insulin binding
What is insulin binding?
Insulin binding is the molecular function (GO:0043559) of binding to insulin, a hormone produced by the pancreas, initiating cellular signaling.
What genes are involved in insulin binding?
Key genes include INS (insulin) and INSR (insulin receptor), as well as IGF1R and downstream signaling molecules.
How is insulin binding measured?
Techniques include fluorescence correlation spectroscopy, radioligand binding assays, and surface plasmon resonance.
What is negative cooperativity in insulin binding?
It is the phenomenon where binding of one insulin molecule reduces the receptor's affinity for additional insulin molecules.
What diseases are associated with defective insulin binding?
Diabetes mellitus, insulin resistance, and autoimmune diabetes are linked to altered insulin binding.
Can CRISPR be used to study insulin binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of insulin binding mechanisms.
What is the role of insulin receptor in insulin binding?
The insulin receptor (INSR) is the primary mediator of insulin binding, activating downstream signaling.
How does insulin Wakayama affect binding?
Insulin Wakayama is a mutant insulin with altered receptor binding affinity, studied using computational and experimental models.
What are insulin-binding B cells?
These are B cells that bind insulin and are implicated in autoimmune diabetes; proinsulin variants can target them.
Why is insulin binding important for drug development?
Understanding binding informs the design of insulin analogs and receptor-targeted therapies for diabetes.
Conclusion
Insulin binding (GO:0043559) is a cornerstone molecular function in metabolic regulation and disease. Its mechanisms, from negative cooperativity to receptor activation, are well-studied and continue to reveal therapeutic opportunities. By leveraging CRISPR models and advanced binding assays, researchers can further unravel the complexities of insulin binding and translate findings into clinical advances.
References
- 1. De Meyts P. 1994. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling.. Diabetologia 37 Suppl 2:S135-48 PMID: 7821729
- 2. Zhong ZH et al.. 2001. Insulin binding monitored by fluorescence correlation spectroscopy.. Diabetologia 44(9):1184-8 PMID: 11596675
- 3. Gambhir KK et al.. 1981. Insulin binding and degradation by human erythrocytes at physiological temperature.. Endocrinology 109(5):1787-9 PMID: 7028468
- 4. Posner BI. 2017. Insulin Signalling: The Inside Story.. Can J Diabetes 41(1):108-113 PMID: 27614806
- 5. Pullen RA et al.. 1976. Receptor-binding region of insulin.. Nature 259(5542):369-73 PMID: 175286
- 6. Apley KD et al.. 2026. Evaluation of proinsulin(F25D) as a targeting ligand for insulin-binding B cells in autoimmune diabetes.. Drug Deliv Transl Res 16(1):303-315 PMID: 40402465
- 7. Barron MP et al.. 2024. A λ-Dynamics Investigation of Insulin Wakayama and Other A3 Variant Binding Affinities to the Insulin Receptor.. J Chem Inf Model 64(14):5657-5670 PMID: 38963805
- 8. Macháčková K et al.. 2019. Mutations at hypothetical binding site 2 in insulin and insulin-like growth factors 1 and 2 result in receptor- and hormone-specific responses.. J Biol Chem 294(46):17371-17382 PMID: 31558604
